Monarch Capital Management Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Monarch Capital Management Inc. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 67.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,345 shares of the biopharmaceutical company’s stock after acquiring an additional 941 shares during the quarter. Monarch Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,231,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Dodge & Cox grew its position in Regeneron Pharmaceuticals by 64.6% during the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the last quarter. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $628,151,000. Acadian Asset Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 234.7% during the second quarter. Acadian Asset Management LLC now owns 465,740 shares of the biopharmaceutical company’s stock worth $244,480,000 after buying an additional 326,583 shares during the last quarter. Loomis Sayles & Co. L P increased its position in Regeneron Pharmaceuticals by 18.6% in the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after acquiring an additional 305,089 shares during the period. Finally, Invesco Ltd. lifted its position in Regeneron Pharmaceuticals by 26.5% during the 2nd quarter. Invesco Ltd. now owns 1,075,824 shares of the biopharmaceutical company’s stock worth $564,808,000 after acquiring an additional 225,078 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $741.29 on Friday. The firm has a 50 day moving average of $664.44 and a 200-day moving average of $592.75. The company has a market cap of $77.91 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 2.12 and a beta of 0.37. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $790.98.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $12.46 EPS. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 7.02% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Canaccord Genuity Group increased their price target on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Cantor Fitzgerald lifted their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Jefferies Financial Group boosted their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. Finally, BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a research report on Thursday, December 4th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $779.45.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.